MX389265B - Aminopirimidinas como inhibidores de alk. - Google Patents
Aminopirimidinas como inhibidores de alk.Info
- Publication number
- MX389265B MX389265B MX2019002393A MX2019002393A MX389265B MX 389265 B MX389265 B MX 389265B MX 2019002393 A MX2019002393 A MX 2019002393A MX 2019002393 A MX2019002393 A MX 2019002393A MX 389265 B MX389265 B MX 389265B
- Authority
- MX
- Mexico
- Prior art keywords
- aminopyrimidines
- formula
- alk inhibitors
- present disclosure
- provides compounds
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380818P | 2016-08-29 | 2016-08-29 | |
| PCT/US2017/048845 WO2018044767A2 (en) | 2016-08-29 | 2017-08-28 | Aminopyrimidines as alk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002393A MX2019002393A (es) | 2019-07-08 |
| MX389265B true MX389265B (es) | 2025-03-20 |
Family
ID=59846649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002393A MX389265B (es) | 2016-08-29 | 2017-08-28 | Aminopirimidinas como inhibidores de alk. |
| MX2022000376A MX2022000376A (es) | 2016-08-29 | 2019-02-27 | Aminopirimidinas como inhibidores de alk. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000376A MX2022000376A (es) | 2016-08-29 | 2019-02-27 | Aminopirimidinas como inhibidores de alk. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10709705B2 (enExample) |
| EP (2) | EP4001273A3 (enExample) |
| JP (2) | JP7094566B2 (enExample) |
| KR (1) | KR102530871B1 (enExample) |
| CN (2) | CN109715620B (enExample) |
| AU (2) | AU2017319135B2 (enExample) |
| CA (1) | CA3033223A1 (enExample) |
| IL (1) | IL264638B (enExample) |
| MX (2) | MX389265B (enExample) |
| NZ (1) | NZ751713A (enExample) |
| SG (2) | SG10201914030UA (enExample) |
| WO (1) | WO2018044767A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3758705A4 (en) | 2018-07-31 | 2021-08-04 | Ascentage Pharma (Suzhou) Co., Ltd. | CANCER TREATMENT METHOD USING A COMBINATION OF FAK / ALK / ROS1 INHIBITOR AND EGFR INHIBITOR |
| CN111171033B (zh) * | 2018-11-09 | 2021-11-02 | 天津大学 | 一种嘧啶衍生物及其合成方法和应用 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CN110143947B (zh) * | 2019-05-29 | 2021-10-15 | 华东师范大学 | 一种色瑞替尼类似物的制备方法 |
| CN113395968B (zh) * | 2019-06-25 | 2024-03-01 | 苏州亚盛药业有限公司 | 用于治疗疾病的fak抑制剂和btk抑制剂的组合 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022063220A1 (en) * | 2020-09-25 | 2022-03-31 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical composition and use thereof for treatment of cancer |
| WO2022222932A1 (en) * | 2021-04-19 | 2022-10-27 | Ascentage Pharma (Suzhou) Co., Ltd. | A pharmaceutical combination and use thereof |
| WO2023106881A1 (ko) * | 2021-12-09 | 2023-06-15 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약학 조성물 |
| CN116332919B (zh) * | 2022-03-30 | 2025-08-26 | 苏州亚盛药业有限公司 | 一种alk抑制剂化合物及其中间体的制备方法 |
| TWI885708B (zh) * | 2023-01-20 | 2025-06-01 | 大陸商蘇州亞盛藥業有限公司 | Alk抑制劑或其鹽、溶劑合物的結晶形式及其製備方法和應用 |
| WO2024193693A1 (zh) * | 2023-03-22 | 2024-09-26 | 苏州亚盛药业有限公司 | 药物组合及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PT2287156E (pt) | 2003-08-15 | 2013-08-26 | Novartis Ag | 2,4-di(fenilamino)-pirimidinas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário |
| CA2538413A1 (en) * | 2003-09-18 | 2005-03-24 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| EP2253614B1 (en) * | 2004-04-07 | 2012-09-19 | Novartis AG | Inhibitors of IAP |
| GEP20125691B (en) | 2006-12-08 | 2012-11-26 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2009126515A1 (en) | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP2627179A4 (en) | 2010-10-14 | 2014-04-02 | Ariad Pharma Inc | METHODS OF INHIBITING CELL PROLIFERATION IN EGFR-INDUCED CANCERS |
| EA023404B1 (ru) * | 2011-02-02 | 2016-05-31 | Новартис Аг | Способ лечения немелкоклеточного рака легких |
| CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
-
2017
- 2017-08-28 EP EP21212760.9A patent/EP4001273A3/en not_active Withdrawn
- 2017-08-28 SG SG10201914030UA patent/SG10201914030UA/en unknown
- 2017-08-28 JP JP2019511664A patent/JP7094566B2/ja active Active
- 2017-08-28 CN CN201780057518.0A patent/CN109715620B/zh active Active
- 2017-08-28 CA CA3033223A patent/CA3033223A1/en active Pending
- 2017-08-28 NZ NZ751713A patent/NZ751713A/en unknown
- 2017-08-28 AU AU2017319135A patent/AU2017319135B2/en active Active
- 2017-08-28 CN CN202210533398.XA patent/CN115043821B/zh active Active
- 2017-08-28 MX MX2019002393A patent/MX389265B/es unknown
- 2017-08-28 SG SG11201901251SA patent/SG11201901251SA/en unknown
- 2017-08-28 US US15/559,445 patent/US10709705B2/en active Active
- 2017-08-28 WO PCT/US2017/048845 patent/WO2018044767A2/en not_active Ceased
- 2017-08-28 EP EP17764949.8A patent/EP3504203B1/en active Active
- 2017-08-28 KR KR1020197007075A patent/KR102530871B1/ko active Active
-
2019
- 2019-02-04 IL IL264638A patent/IL264638B/en unknown
- 2019-02-27 MX MX2022000376A patent/MX2022000376A/es unknown
-
2020
- 2020-06-29 US US16/914,518 patent/US11110090B2/en active Active
-
2021
- 2021-05-14 AU AU2021203098A patent/AU2021203098B2/en active Active
-
2022
- 2022-06-15 JP JP2022096630A patent/JP2022120151A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018044767A2 (en) | 2018-03-08 |
| CN115043821B (zh) | 2024-08-06 |
| AU2017319135B2 (en) | 2021-03-18 |
| CN115043821A (zh) | 2022-09-13 |
| SG10201914030UA (en) | 2020-03-30 |
| US10709705B2 (en) | 2020-07-14 |
| US11110090B2 (en) | 2021-09-07 |
| US20200330464A1 (en) | 2020-10-22 |
| BR112019003897A2 (pt) | 2019-05-21 |
| WO2018044767A3 (en) | 2018-04-12 |
| EP4001273A3 (en) | 2022-08-24 |
| MX2019002393A (es) | 2019-07-08 |
| JP7094566B2 (ja) | 2022-07-04 |
| IL264638B (en) | 2021-08-31 |
| AU2017319135A1 (en) | 2019-04-04 |
| AU2021203098A1 (en) | 2021-06-10 |
| AU2021203098B2 (en) | 2023-05-25 |
| KR102530871B1 (ko) | 2023-05-09 |
| SG11201901251SA (en) | 2019-03-28 |
| EP4001273A2 (en) | 2022-05-25 |
| JP2022120151A (ja) | 2022-08-17 |
| CA3033223A1 (en) | 2018-03-08 |
| EP3504203B1 (en) | 2022-09-28 |
| NZ751713A (en) | 2022-07-01 |
| US20190175595A1 (en) | 2019-06-13 |
| JP2019528307A (ja) | 2019-10-10 |
| CN109715620B (zh) | 2022-05-06 |
| MX2022000376A (es) | 2022-02-10 |
| KR20190039760A (ko) | 2019-04-15 |
| CN109715620A (zh) | 2019-05-03 |
| EP3504203A2 (en) | 2019-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389265B (es) | Aminopirimidinas como inhibidores de alk. | |
| MX2018013433A (es) | Piperidinas como inhibidores de menina. | |
| MX2019011412A (es) | Piperidinas como inhibidores de menina covalentes. | |
| CL2019000368A1 (es) | Inhibidores de cdk2/4/6. | |
| DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
| CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
| CO2018009275A2 (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub) | |
| MX2018012379A (es) | Degradadores de proteinas de bromodominio y dominioextraterminal (bet). | |
| MX2017002656A (es) | Compuestos que inhiben la proteína mcl-1. | |
| MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| CL2015002151A1 (es) | Biaril amide compuestos como inhibidores de quinasa | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| UY38471A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| MX2019003724A (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| MX2018005725A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer. | |
| MX2017003930A (es) | Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank. | |
| MX2022005298A (es) | Compuestos intermediarios de sintesis de inhibidores de a2a. | |
| MA40171A (fr) | Dérivés d'azamophinan et leur utilisation | |
| MX390051B (es) | Antagonistas de ep4. | |
| MX2016010524A (es) | Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico. | |
| CL2019000662A1 (es) | Inhibidores de dopamina–b–hidroxilasa. | |
| CR20150148A (es) | Azaindolinas | |
| PE20150674A1 (es) | Azaheterociclos como inhibidores de bir2 y/o bir3 | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo |